Form 4: Seres Therapeutics EVP Granted 3,998 RSUs

Teresa L. Young, EVP, Chief Commercial & Strategy Officer at Seres Therapeutics, Inc., was granted 3,998 restricted stock units, vesting on November 15, 2025.

Summary

• Teresa L. Young, the Executive Vice President, Chief Commercial & Strategy Officer of Seres Therapeutics, Inc. (MCRB), acquired 3,998 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of the Issuer's common stock.
• The RSUs were granted on September 26, 2025, with a deemed execution date of the same day.
• These RSUs will vest in a single installment on November 15, 2025, contingent upon Ms. Young's satisfaction of the terms outlined in the award agreement.
• Following this transaction, Ms. Young beneficially owns 3,998 derivative securities (RSUs) directly.
• The transaction price for these RSUs was $0, which is typical for RSU grants.

Sentiment

Score: 6

Explanation: The filing reports a routine executive compensation event (RSU grant), which is generally a neutral to slightly positive indicator as it aligns executive interests with shareholders, but does not reflect operational or financial performance.

Positives

• The grant of Restricted Stock Units aligns the executive's interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• This is a routine compensation event, indicating stability in executive remuneration practices.

Future Outlook

The future outlook indicates that the granted Restricted Stock Units are scheduled to vest on November 15, 2025, subject to the reporting person meeting the terms of the award agreement.

Industry Context

The grant of Restricted Stock Units to an executive is a standard practice in the biotechnology and pharmaceutical industries for executive compensation, aiming to incentivize long-term performance and retention by linking compensation to company stock value.

Comparison to Industry Standards

• The grant of Restricted Stock Units (RSUs) as a form of executive compensation is a common practice across publicly traded companies, particularly in the biotech sector, aligning with global benchmarks for performance-based incentives.
• The vesting schedule, a single installment on a future date, is a straightforward approach often seen in similar grants, comparable to practices at companies like Moderna or BioNTech for certain executive awards.

Stakeholder Impact

• Shareholders: The RSU grant aligns the executive's financial interests with shareholder value creation, potentially fostering long-term commitment and performance.

Next Steps

• The 3,998 Restricted Stock Units are expected to vest on November 15, 2025, converting into shares of common stock for the reporting person.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a standard disclosure of insider ownership changes.

Keywords

Seres Therapeutics, MCRB, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Teresa L. Young, Equity Grant